MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 14, 2007; DOI: 10.1124/mol.107.041574


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041574v1
73/3/748    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chanrion, B.
Right arrow Articles by Millan, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chanrion, B.
Right arrow Articles by Millan, M. J.


Received for publication September 7, 2007.
Revised November 22, 2007.
Accepted for publication December 13, 2007.

Inverse Agonist and Neutral Antagonist Actions of Antidepressants at Recombinant and Native 5-HT2C Receptors: Differential Modulation of Cell Surface Expression and Signal Transduction

Benjamin Chanrion 1, Clotilde Mannoury la Cour 2, Sophie Gavarini 1, Mathieu Seimandi 1, Laurent Vincent 3, Jean-Francois Pujol 3, Joel Bockaert 1*, Philippe Marin 1, Mark J. Millan 2

1 CNRS, ISERM, UMI, UMII 2 Institut de recherches Servier 3 Biocortech

* Address correspondence to: E-mail: secretariat{at}igf.cnrs.fr

Abstract

Despite the importance of serotonin (5-HT)2C receptors in the control of depressive states, actions of antidepressants at these receptors remain poorly characterized. This issue was addressed both in HEK-293 cells co-expressing unedited human (h)5-HT2CINI receptors and G[alpha]q protein and in cultured mouse cortical neurons. Indicative of constitutive activity, the inverse agonist, SB206,553, decreased basal inositol phosphate (IP) production in HEK-293 cells. The tetracyclic antidepressants, mirtazapine and mianserin, likewise suppressed basal IP formation. Conversely, the tricyclics, amitriptyline and clomipramine, the m-chlorophenylpiperazine derivatives, trazodone and nefazodone, and the 5-HT reuptake inhibitors, fluoxetine and citalopram, were inactive alone though they blocked 5-HT-induced IP production. Inverse agonist actions of SB206,553 and mirtazapine were abolished by the neutral antagonist, SB242,084, which was inactive alone. As assessed by confocal microscopy and ELISA, prolonged treatment of HEK-293 cells with SB206,553, mirtazapine or mianserin, but not the other antidepressants, enhanced cell surface expression of 5-HT2C receptors: 5-HT-induced IP production was also increased, and both these actions were blocked by SB242,084. Cortical neurons were shown by RT-PCR to predominantly express constitutively-active 5-HT2C receptor isoforms. Prolonged pretreatment with SB206,553 or mirtazapine triggered an otherwise-absent, 5-HT-induced elevation in cytosolic Ca2+ concentrations. SB242,084, which was inactive alone, abolished these effects of SB206,553 and mirtazapine. In conclusion, the tetracyclic antidepressants, mirtazapine and mianserin, but not other clinically-established antidepressants, suppress constitutive activity at recombinant and native 5-HT2C receptors. The clinical significance of inverse agonist vs. neutral antagonist properties both during and following drug administration will be of interest to elucidate.


Key words: Serotonin, Phospholipase C's, Alternative splicing/RNA editing, Receptor synthesis/trafficking, Sequestration/Internalization, Recycling, Ca imaging, Immunocytochemistry, Anti-depressants





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics